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Only a few studies have reported the alteration of enteric nervous system (ENS) related to GI dysfunction in PD. 2, 3 Wang et al 4 recently reported age-related alterations in colonic myenteric ganglia and defecation using mice overexpressing wild-type human α-synuclein under the Thy-1 promoter (Thy1-aSyn). They previously reported that 12 months old mice overexpressing α-synuclein exhibited increased colonic transit time and content compared with wild-type. 5 In current experiment, they investigated whether the onset of colonic motor dysfunction in Thy1-aSyn mice occurred at earlier lifetime. When mice were exposed to novel environment which consisted of placing singly in a new cage without food, Thy1-aSyn mice aged 2.5-3 and 7-8 months exhibited decreased fecal pellet expulsion at 15 min compared to control. While 2.5-3 months old mice did not show significant reduction in the 30-60 minutes, 7-8 months old mice had continuous reduction during 15-60 minutes. These mice subsequently were re-fed during 2 hours and showed significantly decreased fecal pellet output compared to controls in both age. Interestingly, there was no significant change in gastric emptying in Thy1-aSyn mice. Colonic tyrosine hydroxylase, vasoactive intestinal polypeptide (VIP), peripheral choline acetyltransferase (pChAT) and neuronal nitric oxide synthase (nNOS) immunoreactivity were not significantly different between Thy1-aSyn mice and control. However, the staining for α-synuclein was 3-fold higher in Thy1-aSyn mice compared to control and it was mainly localized to varicosities adjacent to pChAT immunoreactive neuronal fibers. Authors concluded that α-synuclein is overproduced in the ENS earlier than the loss of striatal dopamine, and enteric neurotransmitters such as dopamine, VIP and nitric oxide may not be important in the colon dysmotility at least in the early stage of PD.
Comment
PD has not only motor symptoms but also multiple GI symptoms including salivary excess, dysphagia, nausea, delayed gastric emptying, and constipation. 6 Constipation is the most prominent GI symptom of PD and their prevalence ranged from 20-89% in various studies. 6 Constipation occurs at all stages of PD, even in a preclinical stage. 1, 6 Savica et al 7 reviewed medical records of 169 subjects who developed PD in Omsted county and investigated the relationship between constipation and PD. They found that constipation precedes the classic motor signs of PD up to 20 years and suggested that constipation might be an early manifestation of the neurodegenerative process underlying PD. 7 In spite of their high prevalence, pathophysiology of constipation in PD has not been investigated in detail and the pathological changes in the ENS of PD still need to be elucidated. 1 Damage of the ENS in PD is the most plausible explanation for GI dysfunction. So far, it has not been clear whether enteric neurons are damaged, or to what extent they are impaired in PD. 1 One study using colectomy specimen from patients with PD showed dopaminergic neuronal loss in the colonic myenteric plexus and submucosal plexus, whereas other types of neurons were not affected. 8 nNOS and VIP immunoreactive neurons in the GI tract also could be affected in PD. 9 However, study using colonic biopsies from patients with PD showed no definite neuronal loss in the submucosal plexus. 10 The accumulation of specific pathologic material, such as α-synuclein, in the ENS also may cause GI dysfunction in PD.
The presence of LB and Lewy neurites has been demonstrated in the ENS of patients with PD in several studies. 9, 11 In the immunohisochemical staining from autopsy specimen of patients with PD, α-synuclein immunoreactive aggregations were found in the gastric myenteric and submucosal plexuses. 12 Lewy neurites immunoreactive for both neurofilament and α-synuclein were found in the colonic biopsies and the amount of Lewy neurites in the ENS was positively correlated with constipation. 13 In current study, Wang et al 4 demonstrated that neuronal loss of ENS is not required in dysmotility at least in early stage PD because there was no obvious colonic neuronal loss in the Thy1-aSyn mice. Instead, they suggested that accumulated α-synuclein around pChAT myenteric neurons alters inputs to cholinergic neurons and it may contribute to decreased colonic motility. Because constipation occurs before motor symptom 7 and pathologic alterations in the ENS can occur during the early stage of PD even before the central nervous system is affected, 8, [10] [11] [12] it was suggested that the GI tract is an early target of PD. 14 In line with clinical findings, Wang et al 4 demonstrated
that older group had more reduction in fecal pellet output compared to younger group. This finding indicates progression in the alteration of the defecation response to stress with age in PD.
Because of the difficulty in discovering pathological changes of the ENS in patient with PD and their heterogeneous pathophysiology, appropriate animal models are required in the study of PD.
1 Current animal models of PD can be categorized into genetic and neurotoxic models. 15 Unfortunately, neither of these models exhibited motor symptom, neurodegeneration such as loss of dopamine neuron, and LB accumulation all together. Wang et al 4 used mice overexpressing human α-synuclein to investigate colonic neuronal change in PD. However, these mice do not have delayed gastric emptying which is highly prevalent in patient with PD. 6 Although this genetic model was created based on potential mechanism which was identified in PD, it does not exhibit neurodegeneration and phenotypes which are observed in PD. 2 Toxin models exhibit motor symptom and peripheral neurochemical damage, whereas they have some drawbacks such as the different time factor from human condition. 2, 9, 16 Therefore, it is important to select an appropriate animal model for target symptoms which is the primary interest in the experiment of PD. 2 The discovery of alteration in the ENS in PD using animal models may help us to find new therapeutic target for GI dysfunction and offer better patient care in this chronic disease.
